NCT02652052View on ClinicalTrials.gov

Hematopoietic Stem Cell Transplant Survivors Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Stem Cell Transplant
Interventions
OTHER

Standard of Care - Observation Only

Control Arm - Observation only

DRUG

Group 2: Quercetin

Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.

DRUG

Group 2: Dasatinib

Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER